Zynerba Pharmaceuticals Inc logo

ZYNE - Zynerba Pharmaceuticals Inc Share Price

$3.58 0.0  0.0%

Last Trade - 22/01/21

Small Cap
Market Cap £76.7m
Enterprise Value £29.9m
Revenue £n/a
Position in Universe 4796th / 6626
Unlock ZYNE Revenue
Relative Strength (%)
1m -0.30%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -51.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.81 0.28 0.007 0.000 0.086 0.000 0.57 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, ZynerbaPharmaceuticals Inc revenues was not reported. Net lossincreased 88% to $41.7M. Higher net loss reflects Researchand development - Balancing val increase from $13.2M to$28.5M (expense), General and administrative - Balancing vincrease of 26% to $9.5M (expense), Interest incomedecrease of 81% to $239K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ZYNE Revenue Unlock ZYNE Revenue

Net Income

ZYNE Net Income Unlock ZYNE Revenue

Normalised EPS

ZYNE Normalised EPS Unlock ZYNE Revenue

PE Ratio Range

ZYNE PE Ratio Range Unlock ZYNE Revenue

Dividend Yield Range

ZYNE Dividend Yield Range Unlock ZYNE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZYNE EPS Forecasts Unlock ZYNE Revenue
Profile Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 31, 2007
Public Since August 5, 2015
No. of Shareholders: 31
No. of Employees: 28
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 29,439,175
Free Float (0.0%)
Eligible for
ZYNE Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ZYNE
Upcoming Events for ZYNE
Frequently Asked Questions for Zynerba Pharmaceuticals Inc
What is the Zynerba Pharmaceuticals Inc share price?

As of 22/01/21, shares in Zynerba Pharmaceuticals Inc are trading at $3.58, giving the company a market capitalisation of £76.7m. This share price information is delayed by 15 minutes.

How has the Zynerba Pharmaceuticals Inc share price performed this year?

Shares in Zynerba Pharmaceuticals Inc are currently trading at $3.58 and the price has moved by -37.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zynerba Pharmaceuticals Inc price has moved by -46.06% over the past year.

What are the analyst and broker recommendations for Zynerba Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Zynerba Pharmaceuticals Inc, there are there are currently 2 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zynerba Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Zynerba Pharmaceuticals Inc next release its financial results?

Zynerba Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Zynerba Pharmaceuticals Inc dividend yield?

Zynerba Pharmaceuticals Inc does not currently pay a dividend.

Does Zynerba Pharmaceuticals Inc pay a dividend?

Zynerba Pharmaceuticals Inc does not currently pay a dividend.

When does Zynerba Pharmaceuticals Inc next pay dividends?

Zynerba Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Zynerba Pharmaceuticals Inc shares?

To buy shares in Zynerba Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zynerba Pharmaceuticals Inc?

Shares in Zynerba Pharmaceuticals Inc are currently trading at $3.58, giving the company a market capitalisation of £76.7m.

Where are Zynerba Pharmaceuticals Inc shares listed? Where are Zynerba Pharmaceuticals Inc shares listed?

Here are the trading details for Zynerba Pharmaceuticals Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: ZYNE
What kind of share is Zynerba Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Zynerba Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zynerba Pharmaceuticals Inc share price forecast 2021?

Shares in Zynerba Pharmaceuticals Inc are currently priced at $3.58. At that level they are trading at 0.107% discount to the analyst consensus target price of 0.00.

Analysts covering Zynerba Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.913 for the next financial year.

How can I tell whether the Zynerba Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zynerba Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -15.66%. At the current price of $3.58, shares in Zynerba Pharmaceuticals Inc are trading at -11.37% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zynerba Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Zynerba Pharmaceuticals Inc.

Who are the key directors of Zynerba Pharmaceuticals Inc?

Zynerba Pharmaceuticals Inc's management team is headed by:

Armando Anido - CHM
Terri Sebree - PRE
Suzanne Hanlon - VPR
Warren Cooper - LED
William Federici - IND
Daniel Kisner - IND
Kenneth Moch - IND
Brian Rosenberger - VPR
James Fickenscher - CFO
John Butler - IND
Who are the major shareholders of Zynerba Pharmaceuticals Inc?

Here are the top five shareholders of Zynerba Pharmaceuticals Inc based on the size of their shareholding:

ETF Managers Group, LLC Investment Advisor
Percentage owned: 6.8% (2.00m shares)
ETFMG Alternative Harvest ETF Mutual Fund
Percentage owned: 6.16% (1.81m shares)
Rapoport (Michael D) Individual Investor
Percentage owned: 5.06% (1.49m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.11% (917k shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.09% (615k shares)
Similar to ZYNE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.